Previous 10 | Next 10 |
ChromaDex Corp. (NASDAQ:CDXC) today announced that it will be participating at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private 1:1 ...
2023-05-11 18:12:08 ET ChromaDex Corporation (CDXC) Q1 2023 Results Conference Call May 10, 2023 04:30 PM ET Company Participants Kendall Knysch - Director, Media Relations Rob Fried - Chief Executive Officer Brianna Gerber - Chief Financial Officer Andrew Sh...
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2023 Investor Conference. Mr. Fried and Mrs. Ger...
2023-05-10 16:16:17 ET ChromaDex press release ( NASDAQ: CDXC ): Q1 GAAP EPS of -$0.03 beats by $0.02 . Revenue of $22.56M (+30.7% Y/Y) beats by $3.24M . “We raised the conservative end of our 2023 revenue outlook to 12.5% growth and, importantly, are se...
Record net sales of $22.6 million, with a strong gross margin of 59.9%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.9 million and $0.1 million, respectively, for the three months ended March 31, 2023. ChromaDex Corp. (NASDAQ:CDXC) today announced financi...
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, May 10, 2023 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2023. The fi...
2023-03-09 00:10:21 ET The following slide deck was published by ChromaDex Corporation in conjunction with their 2022 Q4 earnings call. For further details see: ChromaDex Corporation 2022 Q4 - Results - Earnings Call Presentation
2023-03-08 21:42:09 ET ChromaDex Corporation (CDXC) Q4 2022 Earnings Conference Call March 08, 2023 4:30 PM ET Company Participants Tom Shumaker – LifeSci Advisors, Agency IR Counsel Rob Fried – Chief Executive Officer Brianna Gerber – Chief ...
2023-03-08 16:07:25 ET ChromaDex press release ( NASDAQ: CDXC ): Q4 GAAP EPS of -$0.02 beats by $0.01 . Revenue of $21M (+18.0% Y/Y) beats by $0.12M . Looking forward, for the full year, the Company expects at least 10% revenue growth, with a realistic possibil...
Record revenue in Q4 2022 with $21.0 million in total net sales, up 18% from the prior year quarter, a net loss of $1.4 million and an Adjusted EBITDA profit of $0.4 million. Full year total net sales of $72.0 million with $60.1 million from Tru Niagen ChromaDex Corp. (NASDAQ:CDXC) ...
News, Short Squeeze, Breakout and More Instantly...
ChromaDex Corporation Company Name:
CDXC Stock Symbol:
NASDAQ Market:
ChromaDex Corporation Website:
U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper...
ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen ® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD +...
NR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research, shares results from a milestone phase II clinical study showcasing the promising effe...